← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Rfe Pharma, Inc.
Alachua, FL
$2,253,719
Total funding
8
Grants
Funding over time
peak $553.2K · FY2005–07$1M$750K$500K$250K$0
'05
'06
'07
Funding mix
By agency
NIH$2,253,719 · 8
By mechanism
R42$1,565,986 · 2
R41$687,733 · 6
Investigators at Rfe Pharma, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Non-Peptide Somatostatin Agonist Analgesics$414,814
R42 · FY2006 · NS
Non-Peptide Somatostatin Agonist Analgesics$401,172
R42 · FY2007 · NS
Nonpeptide Somatostatin Agonists for Retinopathy$375,000
R42 · FY2004 · EY
Nonpeptide Somatostatin Agonists for Retinopathy$375,000
R42 · FY2005 · EY
Carboxyamidotriazole for Neovascular Ocular Disease$151,994
R41 · FY2007 · EY
Ocular Delivery of Non-Peptide Somatostatin Agonists$134,820
R41 · FY2004 · EY
Somatostatin Mimetics as Novel Anti-Epileptic Drugs$101,352
R41 · FY2003 · NS
Nonpeptide Somatostatin Agonists for Retinopathy$100,000
R41 · FY2003 · EY
Chiral CE for Non Peptide Somatostatin Drugs$100,000
R41 · FY2003 · DK
Non-Peptide Somatostatin Agonist Analgesics$99,567
R41 · FY2004 · NS